Clinical trials: Migraines
Chronic Migraine
Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- NCT04829747
- Testing
- Atogepant
- Where
- 3 sites in China
- Volunteers
- 3 people
- Sponsor
- Allergan
Acute Migraine
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine. BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant).
- Trial name
- NCT04408794
- Testing
- Zavegepant (BHV-3500)
- Where
- 67 sites in United States
- Volunteers
- 974 people
- Sponsor
- Pfizer
Hypertension, Heart Failure
LSFG-SKIN, Laser Speckle Flowgraphy
The purpose of this project is to quantify normal and abnormal skin blood flow regionally in different areas of the body(face, extremities, over burns and wounds) at baseline and over time in response to treatment or…
- Conditions
- Hypertension, Heart Failure, Vascular Ischemia, Burns
- Trial name
- NCT03660618
- Testing
- laser speckle flowgraphy
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Randy Kardon
Migraine
Randomized Trial in Adult Participants With Acute Migraines
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT04571060
- Testing
- Zavegepant
- Where
- 94 sites in United States
- Volunteers
- 1,978 people
- Sponsor
- Pfizer
Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
The reason for this study is to see if the drug galcanezumab is safe and effective in participants with episodic migraine. The study will last about 53 weeks and may include up to 12 visits.
- Trial name
- PERSIST (NCT03963232)
- Testing
- Galcanezumab
- Where
- 40 sites in China, India and 1 more
- Volunteers
- 520 people
- Sponsor
- Eli Lilly and Company
Migraine
Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention
Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment.
- Trial name
- NCT04828707
- Testing
- Nerivio active device
- Where
- 16 sites in United States
- Volunteers
- 335 people
- Sponsor
- Theranica
Migraine, Acute Treatment of Migraine
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain")…
- Trial name
- NCT01430442
- Testing
- Rimegepant, Sumatriptan
- Where
- 41 sites in United States
- Volunteers
- 1,026 people
- Sponsor
- Pfizer
Migraine
Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
To evaluate the long-term safety and tolerability of subcutaneous (SC) administration of TEV-48125 (at 225 mg once monthly [except for a loading dose of 675 mg for CM patients] or at 675 mg every 3 months) for the preventive…
- Trial name
- NCT03303105
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Migraine, With or Without Aura
Safety and Efficacy Study in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
- Trial name
- NCT03235479
- Testing
- Rimegepant
- Where
- 50 sites in United States
- Volunteers
- 1,485 people
- Sponsor
- Pfizer
Migraine, With or Without Aura
Safety and Efficacy in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
- Trial name
- NCT03237845
- Testing
- Rimegepant
- Where
- 50 sites in United States
- Volunteers
- 1,499 people
- Sponsor
- Pfizer
Migraine, With or Without Aura
Open Label Safety Study in Acute Treatment of Migraine
The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
- Trial name
- NCT03266588
- Testing
- Rimegepant
- Where
- 98 sites in United States
- Volunteers
- 3,019 people
- Sponsor
- Pfizer
Migraine, With or Without Aura
Trial in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.
- Trial name
- NCT03461757
- Testing
- Rimegepant
- Where
- 69 sites in United States
- Volunteers
- 1,811 people
- Sponsor
- Pfizer
Chronic Migraine
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
- Trial name
- NCT03855137
- Testing
- Atogepant 30 mg, Atogepant 60 mg
- Where
- 150 sites in United States, Australia and 15 more
- Volunteers
- 778 people
- Sponsor
- Allergan
Migraine Headache
Efficacy, Tolerability, and Safety Study of DFN-15
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States.
- Trial name
- NCT03006276
- Testing
- DFN-15 Active
- Where
- 45 sites in United States
- Volunteers
- 622 people
- Sponsor
- BioDelivery Sciences International
Migraine Headache
Efficacy, Tolerability, and Safety of DFN-15
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States
- Trial name
- NCT03009019
- Testing
- DFN-15 Active
- Where
- 43 sites in United States
- Volunteers
- 631 people
- Sponsor
- BioDelivery Sciences International
Migraine
Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches
The purpose of this research is to assess how well the Avulux® migraine lenses work in reducing the impact of migraine headaches as measured by improvement in an 11-point pain scale after two and four hours of device application…
- Trial name
- NCT04341298
- Testing
- 11-point pain scale, Headache diary, Avulux®
- Where
- 3 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Avulux, Inc.
Headache Migraine Chronic
Spectacle Tints and Thin-Films for Migraine
Nearly all migraine sufferers report sensitivity to light during a headache and a significant proportion of sufferers report light sensitivity between attacks. Light is also a common trigger for migraine headaches.
- Trial name
- NCT02720211
- Testing
- Gray tinted spectacle lenses, Thin-Film spectacle lenses
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Utah
Migraine Disorders, Photophobia
Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine
The purpose of this study is to determine if a special coating, applied to the surface of glasses can reduce the frequency and severity of migraine headaches in children and adolescents.
- Trial name
- NCT01942486
- Testing
- Investigational Coating
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Utah
Migraine
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
A study to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days in participants with episodic migraine.
- Trial name
- NCT01952574
- Testing
- Erenumab, Erenumab PFS, Erenumab AI/Pen
- Where
- 66 sites in United States, Canada and 5 more
- Volunteers
- 483 people
- Sponsor
- Amgen
Treatment for Prevention of Chronic Migraine
A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
To evaluate the effect of erenumab compared to placebo on the change from baseline in the number of monthly migraine days in adults with chronic migraine.
- Trial name
- NCT02066415
- Testing
- Erenumab
- Where
- 74 sites in United States, Canada and 8 more
- Volunteers
- 667 people
- Sponsor
- Amgen